pSivida breaks BrachySil into Chinese market
This article was originally published in Clinica
Australian bio-nanotech company pSivida has licensed its BrachySil technology to Beijing Med-Pharm for marketing and distribution in the Chinese market. Under the terms of the agreement, pSivida will pay its newly-appointed distributor upfront and milestone payments totalling more than $2m for clinical development of the product and securing regulatory approval, as well as royalties of up to 30% on future sales. The Perth-based company will retain the manufacturing rights to BrachySil.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.